Selatogrel

N/A

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameSelatogrel
Drug Alias NameACT-246475
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPurinergic receptor P2Y12 antagonists
TargetsPurinergic receptor P2Y12
Therapy Area/IndicationsChronic Coronary SyndromeMyocardial InfarctionCoronary Artery Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[43] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesIdorsia Pharmaceuticals LtdActelion Pharmaceuticals LtdViatris Innovation (Beijing) Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesViatris Innovation GmbHViatris Innovation (Beijing) Pharmaceuticals Co LtdIdorsia Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsChronic Coronary SyndromeMyocardial Infarction
Inactive IndicationsCoronary Artery DiseaseHepatic Insufficiency

Other Information

ATC CodeN/A
Related LinksN/A